Harold Bernstein, President of Research and Development and Chief Medical Officer at Maze Therapeutics, Inc. (NASDAQ:MAZE), sold 9,705 shares of common stock on September 4, 2026, according to an SEC Form 4 filing.
Metric
Value
Transaction value
~$255,000
#value #president #Research #medical
Metric
Value
Transaction value
~$255,000
#value #president #Research #medical
21 hours ago
